• Dong-A ST presented preclinical results for topical icotrokinra for psoriasis at AAPS PharmSci 360 2026, held Oct. 25-28 in New Orleans.
• The optimized formulation penetrated the skin barrier and retained icotrokinra in targeted skin layers in ex vivo testing.
• Animal studies showed reduced inflammation, with significant suppression of gene expression for key psoriasis-related inflammatory cytokines.
• The findings support continued development as a topical drug candidate, but clinical safety and efficacy require further study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A ST Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260930BIZWIRE_USPR_____20261026_BW151553) on October 26, 2026, and is solely responsible for the information contained therein.